FCCC LOGO Faculty Publications
Astsaturov I , Cohen RB , Harari PM
EGFR-targeting monoclonal antibodies in head and neck cancer
Current Cancer Drug Targets. 2006 Dec;6(8) :691-710
PMID: ISI:000242331700005   
Back to previous list
Abstract
The epidermal growth factor (EGF) and its receptor were discovered nearly 40 years ago. Over the past decade interruption of this pathway has been exploited in the treatment of various solid tumors. Antibodies that interfere with ligand binding to and dimerization of the EGFR (and small molecules that inhibit the EGFR tyrosine kinase) are anti-proliferative, radiosensitizing, and synergistic with DNA-damaging cytotoxic agents. Proposed mechanisms of radio- and. chemosensitization include enhanced apoptosis, interference with DNA repair and angiogenesis, receptor depletion from the cell surface and antibody-dependent cell-mediated cytotoxicity. This article provides the reader with a comprehensive review of EGFR-targeting antibodies under development for the treatment of head and neck squamous cell cancer (HNSCC) and also summarizes relevant clinical data in this disease with small molecule EGFR inhibitors. One of the monoclonal antibodies, cetuximab, recently received full FDA approval for the treatment of patients with locoregionally advanced (with radiation) or metastatic HNSCC (as a single agent). Regulatory approval followed reporting of a large international study in which the addition of cetuximab to definitive radiation therapy in HNSCC resulted in statistically significant improvements in locoregional control and overall survival. Results of the pivotal trial, other clinical data supporting the regulatory approval, and a preview of the next generation of clinical trials are presented. Considerable work remains to be done, particularly to enhance our understanding of factors that may predict for favorable response to EGFR inhibitor therapy and to evaluate the impact of integrating anti-EGFR therapies into complex chemoradiation programs delivered with curative intent.
Notes
ISI Document Delivery No.: 109TM Times Cited: 0 Cited Reference Count: 143 Cited References: ADELSTEIN DJ, 2003, J CLIN ONCOL, V21, P92 AGUILAR RC, 2005, P NATL ACAD SCI USA, V102, P2679 AKIMOTO T, 1999, CLIN CANCER RES, V5, P2884 ANG KK, 2002, CANCER RES, V62, P7350 ATKINS D, 2004, J HISTOCHEM CYTOCHEM, V52, P893 BALABAN N, 1996, BBA-MOL CELL RES, V1314, P147 BANDYOPADHYAY D, 1998, J BIOL CHEM, V273, P1568 BASELGA J, 1993, J NATL CANCER I, V85, P1327 BASELGA J, 2000, J CLIN ONCOL, V18, P904 BASELGA J, 2005, J CLIN ONCOL, V23, P5568 BAUJAT B, 2006, INT J RADIAT ONCOL, V64, P47 BENCHALAL M, 1995, RADIOTHER ONCOL, V36, P203 BIER H, 1998, CANCER IMMUNOL IMMUN, V46, P167 BONNER JA, 2000, J CLIN ONCOL, V18, P47 BONNER JA, 2006, NEW ENGL J MED, V354, P567 BOURHIS J, 2006, J CLIN ONCOL, V24, P2866 BRIZEL DM, 1998, NEW ENGL J MED, V338, P1798 BURTNESS B, 2005, J CLIN ONCOL, V23, P8646 BUSAM KJ, 2001, BRIT J DERMATOL, V144, P1169 CALAIS G, 1999, J NATL CANCER I, V91, P2081 CARTER P, 2001, NAT REV CANCER, V1, P118 CARTRON G, 2002, BLOOD, V99, P754 CARVALHO AL, 2005, INT J CANCER, V114, P806 CHAN ATC, 2005, J CLIN ONCOL, V23, P3568 CHUA DTT, 2004, INT J RADIAT ONCOL, V59, P11 CHUNG KY, 2005, J CLIN ONCOL, V23, P1803 CIARDIELLO F, 2000, CLIN CANCER RES, V6, P3739 CLYNES R, 1998, P NATL ACAD SCI USA, V95, P652 CLYNES RA, 2000, NAT MED, V6, P443 COHEN EEW, 2003, J CLIN ONCOL, V21, P1980 COHEN EEW, 2005, CLIN CANCER RES, V11, P8418 COHEN S, 1965, DEV BIOL, V12, P394 COHEN S, 1980, J BIOL CHEM, V255, P4834 CROMBET T, 2003, J IMMUNOTHER, V26, P139 CROMBET T, 2004, J CLIN ONCOL, V22, P1646 CUNNINGHAM D, 2004, NEW ENGL J MED, V351, P337 DAMIANO V, 2006, CLIN CANCER RES, V12, P577 DASSONVILLE O, 1993, J CLIN ONCOL, V11, P1873 DITTMANN K, 2005, J BIOL CHEM, V280, P31182 DOWNWARD J, 1984, NATURE, V307, P521 ELKIND MM, 1987, BR J CANCER S, V8, P24 ELKIND MM, 1988, RADIAT RES, V114, P425 ENSINGER C, 2004, ANN NY ACAD SCI, V1030, P69 FALLS DL, 2003, EXP CELL RES, V284, P14 FAN Z, 1993, CANCER RES, V53, P4322 FAN Z, 1993, CANCER RES, V53, P4637 FAN Z, 1994, J BIOL CHEM, V269, P27595 FERGUSON KM, 2003, MOL CELL, V11, P507 FORASTIERE AA, 2003, NEW ENGL J MED, V349, P2091 FRIEDMAN LM, 2005, P NATL ACAD SCI USA, V102, P1915 FRIESS T, 2005, CLIN CANCER RES, V11, P5300 FUJII M, 2002, AURIS NASUS LARYNX, V29, P175 GABLER B, 1997, ANTICANCER RES, V17, P3157 GARRETT TPJ, 2002, CELL, V110, P763 GEISLER SA, 2002, CLIN CANCER RES, V8, P3445 GIACCONE G, 2004, J CLIN ONCOL, V22, P777 GORDON AN, 2005, INT J GYNECOL CANCER, V15, P785 GOVINDAN R, 2004, CLIN CANCER RES 2, V10, S4241 GRANDIS JR, 1998, J CLIN INVEST, V102, P1385 HARARI PM, 2001, INT J RADIAT ONCOL, V49, P427 HERBST RS, 2004, J CLIN ONCOL, V22, P785 HERBST RS, 2005, J CLIN ONCOL, V23, P5578 HERBST RS, 2005, J CLIN ONCOL, V23, P5892 HIRSCH FR, 2005, J CLIN ONCOL, V23, P6838 HOLTING T, 1995, EUR J ENDOCRINOL, V132, P229 HSU CH, 2005, ONCOLOGY-BASEL, V68, P538 HUANG SM, 1999, CANCER RES, V59, P1935 HUANG SM, 2000, CLIN CANCER RES, V6, P2166 HUANG SM, 2004, CANCER RES, V64, P5355 HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207 JEMAL A, 2006, CA-CANCER J CLIN, V56, P106 JIMENO A, 2005, CANCER RES, V65, P3003 JOHNS TG, 2004, J BIOL CHEM, V279, P30375 JOHNS TG, 2005, FASEB J, V19, P780 JOHNSON GA, 1997, GYNECOL ONCOL, V65, P425 JOST M, 2000, EUR J DERMATOL, V10, P505 JUNGBLUTH AA, 2003, P NATL ACAD SCI USA, V100, P639 KIM S, 2006, CLIN CANCER RES, V12, P600 KORTYLEWSKI M, 2005, NAT MED, V11, P1314 KRIS MG, 2003, JAMA-J AM MED ASSOC, V290, P2149 KUFE D, 2003, CANC MED, V6 KUFE DW, 2003, AM CANC SOC CANC MED, V6 KWAK EL, 2005, P NATL ACAD SCI USA, V102, P7665 LAUX I, 2006, BRIT J CANCER, V94, P85 LAX I, 1991, CELL REGUL, V2, P337 LEE JW, 2005, CLIN CANCER RES, V11, P2879 LEE SC, 2006, PHARMACOGENET GENOM, V16, P73 LEMMON MA, 1997, EMBO J, V16, P281 LI SQ, 2005, CANCER CELL, V7, P301 LIN SY, 2001, NAT CELL BIOL, V3, P802 LO HW, 2005, CANCER CELL, V7, P575 LOEFFLERRAGY J, 2006, EUR J CANCER, V42, P109 LYNCH TJ, 2004, NEW ENGL J MED, V350, P2129 MASUI H, 1984, CANCER RES, V44, P1002 MATAR P, 2004, CLIN CANCER RES, V10, P6487 MENDELSOHN J, 1988, PROG ALLERGY, V45, P147 MESSA C, 1998, ACTA ONCOL, V37, P285 MILAS L, 2000, CLIN CANCER RES, V6, P701 MILAS L, 2003, INT J RADIAT BIOL, V79, P539 MILAS L, 2004, INT J RADIAT ONCOL, V58, P966 MODJTAHEDI H, 1996, BRIT J CANCER, V73, P228 MODJTAHEDI H, 2003, INT J CANCER, V105, P273 MORONI M, 2005, LANCET ONCOL, V6, P279 NOBUHARA Y, 2005, BRIT J CANCER, V92, P1110 OGISO H, 2002, CELL, V110, P775 PAEZ JG, 2004, SCIENCE, V304, P1497 PANOUSIS C, 2005, BRIT J CANCER, V92, P1069 PAO W, 2005, J CLIN ONCOL, V23, P2556 PERERA RM, 2005, CLIN CANCER RES, V11, P6390 PEREZSOLER R, 2005, J CLIN ONCOL, V23, P5235 PFISTER DG, 2006, J CLIN ONCOL, V24, P1072 PIGNON JP, 2000, LANCET, V355, P949 PURI C, 2005, MOL BIOL CELL, V16, P2704 PUTTI TC, 2002, HISTOPATHOLOGY, V41, P144 ROBERT F, 2001, J CLIN ONCOL, V19, P3234 RUBINGRANDIS J, 1996, CANCER, V78, P1284 SALTZ LB, 2004, J CLIN ONCOL, V22, P1201 SCHIFF BA, 2004, CLIN CANCER RES, V10, P8594 SCHMIDTULLRICH RK, 1994, INT J RADIAT ONCOL, V29, P813 SCHMIDTULLRICH RK, 1997, ONCOGENE, V15, P1191 SEQUIST LV, 2005, CLIN CANCER RES, V11, P5668 SHERIDAN MT, 1997, RADIAT ONCOL INVEST, V5, P180 SHIN DM, 2001, CLIN CANCER RES, V7, P1204 SIBILIA M, 2000, CELL, V102, P211 SIGISMUND S, 2005, P NATL ACAD SCI USA, V102, P2760 SOULIERES D, 2004, J CLIN ONCOL, V22, P77 STEVENSON D, 2005, CANCER RES, V65, P8826 SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602 TANG PA, 2006, EXPERT OPIN PHARMACO, V7, P177 TAO YG, 2004, CELL SIGNAL, V16, P781 TAO YG, 2005, EXP CELL RES, V303, P240 TOULANY M, 2005, RADIOTHER ONCOL, V74, P117 UMANA P, 1999, NAT BIOTECHNOL, V17, P176 USHIRO H, 1980, J BIOL CHEM, V255, P8363 VANHOEFER U, 2004, J CLIN ONCOL, V22, P175 VERED M, 2002, HEAD NECK-J SCI SPEC, V24, P632 VILORIAPETIT A, 2001, CANCER RES, V61, P5090 VILORIAPETIT AM, 2004, INT J RADIAT ONCOL, V58, P914 WANG Y, 2002, MOL CELL BIOL, V22, P7279 WANG Y, 2002, SCI STKE, PL17 WENG WK, 2003, J CLIN ONCOL, V21, P3940 WIKSTRAND CJ, 1998, J NEUROVIROL, V4, P148 WIRTH LJ, 2005, J CLIN ONCOL, V23, P6976